Ultromics receives $55 million funding to expand the early detection of heart failure.
Ultromics, a UK-based company specializing in AI-driven cardiology diagnostics solutions, has announced the successful completion of its Series C funding round, raising $55 million. The funding round was co-led by L&G, Allegis Capital, and Lightrock, with participation from University of Chicago Medicine, UPMC Enterprises (the innovation, commercialisation, and investment arm of UPMC, University of Pittsburgh Medical Center), and existing investors Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University.
The funds raised will be used to expand Ultromics' presence across the US and other key markets, bringing its AI-enhanced diagnostics to hospitals and echo labs. The company is also expanding its product pipeline to include additional cardiac conditions, new distribution channels, and deeper partnerships with health systems and clinical leaders.
In 2025, Ultromics launched EchoGo Score, a new feature that adds AI-driven probability scoring to EchoGo Heart Failure. This innovative technology has shown significant improvements in the detection of Heart Failure with Preserved Ejection Fraction (HFpEF). In clinical studies, EchoGo improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores.
Ultromics' diagnostic technology is expected to help save lives when paired with the latest treatment advances. The company recently received FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024. This latest diagnostic model for cardiac amyloidosis outperformed current clinical risk scores while distinguishing disease from similar conditions.
Victor Westerlind, Managing Director at Allegis Capital, stated that Ultromics is closing a long-standing blind spot in cardiology. Up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease.
Ultromics' EchoGo platform uses AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions without requiring new hardware or disrupting clinical workflows. EchoGo Heart Failure and EchoGo Amyloidosis are now fully reimbursed under the USA's Medicare program, making them scalable across hospitals, clinics, and health systems nationwide.
The AI-driven diagnostics provided by Ultromics' EchoGo® platform not only improve early detection but also enhance cardiac care by detecting subtle patterns and transient events that may not be apparent during manual interpretation. This continuous remote cardiac monitoring helps catch transient abnormalities that might otherwise be missed by traditional intermittent testing, improving early intervention and lowering hospital readmission rates.
Moreover, AI-driven diagnostic support tools integrate seamlessly into cardiology workflows without requiring new hardware, facilitating adoption in diverse settings including community and rural hospitals. This accessibility helps reduce diagnostic disparities linked to geography or patient demographics while increasing efficiency for cardiologists.
In summary, AI is transforming cardiology diagnostics by combining large-scale data analysis, pattern recognition, and real-time clinical decision support to reduce missed or delayed diagnoses of HFpEF and cardiac amyloidosis, ultimately improving patient outcomes and enabling earlier treatment interventions. The funding raised by Ultromics will help accelerate the adoption of these AI-driven diagnostics, making a significant impact in the field of cardiology.
Ultromics' AI-driven cardiology diagnostics solutions, specifically EchoGo Heart Failure and EchoGo Amyloidosis, have shown significant improvements in the detection of Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, respectively. These innovations are expected to help save lives when paired with the latest treatment advances.
The funds raised by Ultromics will be used to expand its product pipeline, including additional cardiac conditions, new distribution channels, and deeper partnerships with health systems and clinical leaders. This is expected to accelerate the adoption of these AI-driven diagnostics in the field of cardiology.
Venture capital firms, including L&G, Allegis Capital, Lightrock, University of Chicago Medicine, UPMC Enterprises, Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University, have shown faith in Ultromics' technology by investing in its Series C funding round, raising $55 million.
By using artificial intelligence to extract hidden disease signals from standard echocardiograms, Ultromics' EchoGo platform enables earlier, more accurate detection of complex heart conditions without requiring new hardware or disrupting clinical workflows. This technology has the potential to reduce diagnostic disparities linked to geography or patient demographics, making quality cardiac care more accessible.
